CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy

CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy

Stratification of the prognosis of pancreatic cancer (PDAC) patients treated by surgery is based solely on clinical variables, such as tumor stage and node status. The development of biomarkers of relapse is needed, especially to drive administration of adjuvant therapy in this at-risk population. O...

Full description

Saved in:
Bibliographic Details
Main Authors: Coralie Schoumacher, Valentin Derangère, Gwladys Gaudillière-Le Dain, Titouan Huppe, David Rageot, Alis Ilie, Angélique Vienot, Christophe Borg, Franck Monnien, Frederic Bibeau, Caroline Truntzer, François Ghiringhelli
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Biomarkers
CD3
CD8
immune score
PDAC
prognostic
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2294563
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items